Literature DB >> 23190931

Successful treatment of hepatitis B virus infection and related cryoglobulinaemic purpura with nucleoside/nucleotide analogues.

Emilio D'Amico, Valeria Pace-Palitti, Enza Di Lembo, Carlo Palazzi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23190931

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  4 in total

1.  Clinicopathological features of cryoglobulinemic glomerulonephritis associated with HBV infection: a retrospective analysis of 8 cases in China.

Authors:  Chen Wang; Zi-Yin Ye; De-Hua Zeng; Fei-Lai Xie; Li-Juan Qu; Zhi-Yong Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

Review 3.  Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC).

Authors:  Cesare Mazzaro; Luigino Dal Maso; Laura Gragnani; Marcella Visentini; Francesco Saccardo; Davide Filippini; Pietro Andreone; Anna Linda Zignego; Valter Gattei; Giuseppe Monti; Massimo Galli; Luca Quartuccio
Journal:  Viruses       Date:  2021-05-30       Impact factor: 5.048

4.  Clinicopathological study of mixed cryoglobulinemic glomerulonephritis secondary to hepatitis B virus infection.

Authors:  Chao Li; Hang Li; Wei Su; Yu-Bing Wen; Wei Ye; Wen-Ling Ye; Jian-Fang Cai; Xu-Zhen Qin; Xue-Mei Li; Xue-Wang Li
Journal:  BMC Nephrol       Date:  2020-09-14       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.